JP7701734B2 - 抗aベータワクチン療法 - Google Patents

抗aベータワクチン療法 Download PDF

Info

Publication number
JP7701734B2
JP7701734B2 JP2021569155A JP2021569155A JP7701734B2 JP 7701734 B2 JP7701734 B2 JP 7701734B2 JP 2021569155 A JP2021569155 A JP 2021569155A JP 2021569155 A JP2021569155 A JP 2021569155A JP 7701734 B2 JP7701734 B2 JP 7701734B2
Authority
JP
Japan
Prior art keywords
vaccine composition
administered
disease
amyloid
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021569155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533422A (ja
JP2022533422A5 (cg-RX-API-DMAC7.html
Inventor
ファイファー,アンドレア
ムース,アンドレアス
Original Assignee
エイシー イミューン ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイシー イミューン ソシエテ アノニム filed Critical エイシー イミューン ソシエテ アノニム
Publication of JP2022533422A publication Critical patent/JP2022533422A/ja
Publication of JP2022533422A5 publication Critical patent/JP2022533422A5/ja
Application granted granted Critical
Publication of JP7701734B2 publication Critical patent/JP7701734B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021569155A 2019-05-21 2020-05-20 抗aベータワクチン療法 Active JP7701734B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP19175810.1 2019-05-21
EP19175810 2019-05-21
EP19185593.1 2019-07-10
EP19185593 2019-07-10
EP20171549 2020-04-27
EP20171549.7 2020-04-27
EP20172205 2020-04-29
EP20172205.5 2020-04-29
PCT/EP2020/064172 WO2020234405A1 (en) 2019-05-21 2020-05-20 Anti-abeta vaccine therapy

Publications (3)

Publication Number Publication Date
JP2022533422A JP2022533422A (ja) 2022-07-22
JP2022533422A5 JP2022533422A5 (cg-RX-API-DMAC7.html) 2023-05-29
JP7701734B2 true JP7701734B2 (ja) 2025-07-02

Family

ID=70740677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569155A Active JP7701734B2 (ja) 2019-05-21 2020-05-20 抗aベータワクチン療法

Country Status (15)

Country Link
US (1) US20220226447A1 (cg-RX-API-DMAC7.html)
EP (1) EP3972633A1 (cg-RX-API-DMAC7.html)
JP (1) JP7701734B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220010552A (cg-RX-API-DMAC7.html)
CN (1) CN113853214A (cg-RX-API-DMAC7.html)
AU (1) AU2020277682A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021023209A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138145A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003051A1 (cg-RX-API-DMAC7.html)
IL (1) IL288252B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021014102A (cg-RX-API-DMAC7.html)
MY (1) MY210394A (cg-RX-API-DMAC7.html)
SG (1) SG11202112329RA (cg-RX-API-DMAC7.html)
TW (1) TW202110425A (cg-RX-API-DMAC7.html)
WO (1) WO2020234405A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI916375B (zh) * 2020-06-25 2026-03-01 英商梅迪繆思有限公司 軸突損傷之預防
WO2024156912A1 (en) * 2023-01-26 2024-08-02 Ac Immune Sa Anti-abeta vaccine therapy
WO2025109524A1 (en) * 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014531455A (ja) 2011-09-23 2014-11-27 エーシー イミューン ソシエテ アノニム ワクチン療法
JP2021521149A (ja) 2018-04-10 2021-08-26 エイシー イミューン ソシエテ アノニム 抗−aベータ治療用ワクチン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
CA2633399C (en) * 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
MX2011009654A (es) * 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP2632434B1 (en) 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014531455A (ja) 2011-09-23 2014-11-27 エーシー イミューン ソシエテ アノニム ワクチン療法
JP2021521149A (ja) 2018-04-10 2021-08-26 エイシー イミューン ソシエテ アノニム 抗−aベータ治療用ワクチン

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOS ONE,2016年,Vol. 11, No.3, e0152471

Also Published As

Publication number Publication date
IL288252A (en) 2022-01-01
JP2022533422A (ja) 2022-07-22
MY210394A (en) 2025-09-18
KR20220010552A (ko) 2022-01-25
CN113853214A (zh) 2021-12-28
CA3138145A1 (en) 2020-11-26
SG11202112329RA (en) 2021-12-30
IL288252B1 (en) 2026-06-01
TW202110425A (zh) 2021-03-16
US20220226447A1 (en) 2022-07-21
WO2020234405A1 (en) 2020-11-26
BR112021023209A2 (pt) 2022-01-18
MX2021014102A (es) 2022-02-11
EP3972633A1 (en) 2022-03-30
CL2021003051A1 (es) 2022-07-22
AU2020277682A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
Monsonego et al. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease
Zhang et al. Curcuminoids enhance amyloid-β uptake by macrophages of Alzheimer's disease patients
TWI508975B (zh) 單株抗體
Fiala et al. Ineffective phagocytosis of amyloid-β by macrophages of Alzheimer's disease patients
JP5889529B2 (ja) アミロイド原性疾患の処置
Tuohy et al. Diversity and plasticity of self recognition during the development of multiple sclerosis.
US12324855B2 (en) Method of safe administration of phosphorylated Tau peptide vaccine
KR101152557B1 (ko) 치료 백신
KR20030066695A (ko) 베타 아밀로이드 펩티드를 인식하는 인간화된 항체
RU2011144307A (ru) Фармацевтическая композиция
US20220226447A1 (en) Anti-abeta vaccine therapy
US20080248055A1 (en) Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
Gandy et al. Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-β vaccination in nonhuman primates
WO2015165980A2 (en) Treatment and prevention of alzheimer's disease (ad)
Shao et al. Infiltration of the inflamed eye by NKT cells in a rat model of experimental autoimmune uveitis
HK40058406A (en) Anti-abeta vaccine therapy
EA049756B1 (ru) Терапия с помощью вакцины против бета-амилоида
US20080226668A1 (en) Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
US20050250691A1 (en) Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
JP2026503655A (ja) 抗Aβワクチン療法
US8871226B2 (en) Methods and compositions for the treatment and diagnosis of cancer
US20250049900A1 (en) Method of safe administration of tau phosphopeptide conjugate
Hoffmann Early neurodegenerative changes in a rat model of multiple sclerosis
Imbimbo P2-301: Reduced brain β-amyloid burden, associated microglia inflammation and spatial memory deficit in hAPP transgenic mice treated for six months with CHF5074, a novel gamma-secretase modulator
De Vidi et al. Posters II

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230519

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250526

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250613

R150 Certificate of patent or registration of utility model

Ref document number: 7701734

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150